Skip to main content
TGTX
NASDAQ Life Sciences

ENHANCE Win: Single 600mg BRIUMVI Infusion Matches Two-Dose Regimen

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$63.537
Mkt Cap
$9.751B
52W Low
$26.76
52W High
$68.03
52W Position info
137% above low
Off High info
6.6% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

TGTX has more than doubled off its 52-week low of $26.76.

Summary

The Phase 3b ENHANCE trial met its primary endpoint: a single 600 mg BRIUMVI infusion matched the approved two-infusion regimen, with comparable infusion reactions and no severe cases. That is the real news here — a one-infusion label could simplify dosing and sharpen BRIUMVI's competitive edge. It sits alongside Q3 revenue of $259.9 million, up 61%, profit of $55.5 million, and 2026 revenue guidance raised to about $1 billion, all reported November 9th. The company also finished enrollment in the subcutaneous ublituximab Phase 3 study, with topline expected around the end of 2026 or in the first quarter of 2027. Evercore ISI kept Outperform but trimmed its price target to $71 from $73.

At the time of this announcement, TGTX was trading at $63.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $26.76 to $68.03. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

TGTX - Latest Insights

TGTX
Nov 09, 2026, 4:33 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $63.55
Real-time Price: $62.74 info
Change: -$0.810 (-1%) info
Market Cap: $9.486B info
TGTX
Nov 09, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $63.00
Real-time Price: $62.74 info
Change: -$0.260 (-0.41%) info
Market Cap: $9.486B info
TGTX
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $58.11
Real-time Price: $62.74 info
Change: +$4.63 (+8%) info
Market Cap: $9.486B info
TGTX
Oct 23, 2026, 11:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $52.44
Real-time Price: $62.74 info
Change: +$10.31 (+20%) info
Market Cap: $9.486B info
TGTX
Aug 05, 2026, 5:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $50.48
Real-time Price: $62.74 info
Change: +$12.26 (+24%) info
Market Cap: $9.486B info